哺乳动物雷帕霉素靶蛋白通路在肝癌中的作用:从分子遗传学到靶向治疗
本文综述哺乳动物雷帕霉素靶蛋白(mTOR)复合物在原发性肝癌(肝细胞癌与肝内胆管癌)分子发病机制中的作用,总结基因组学发现的mTOR通路失调、第一代mTOR抑制剂疗效不理想,以及当前开发更有效抑制剂、筛选生物标志物和联合治疗的研究方向。
要点
- mTORC1调控蛋白合成、糖脂代谢与自噬,mTORC2通过AGC家族激酶尤其蛋白激酶B促进肝脏肿瘤发生。
- 人肝细胞癌与肝内胆管癌样本的基因组学分析显示mTOR复合物频繁失调。
- 第一代mTOR抑制剂在肝脏肿瘤治疗中疗效不理想,当前研究致力于开发更有效抑制剂及联合治疗。
核心结论
- mTOR信号失调显著促进肝细胞癌和肝内胆管癌的分子发病机制。
- mTOR抑制剂(推测需与其他药物联合给药)可能对部分人肝脏肿瘤有效。
研究设计与样本
- 本文为综述,系统总结mTOR信号级联在肝癌中失调的机制、mTOR通路促进肝细胞癌和肝内胆管癌分子发病机制的机制、治疗策略及有效抑制mTOR面临的挑战。
主要发现
- mTOR蛋白形成两种不同复合物:mTORC1和mTORC2。
- mTORC1调控蛋白合成、葡萄糖和脂质代谢及自噬,mTORC2通过调节AGC家族丝氨酸/苏氨酸激酶尤其蛋白激酶B促进肝脏肿瘤发生。
- 人肝细胞癌和肝内胆管癌样本的基因组学分析揭示mTOR复合物频繁失调。
- 体外和体内研究均证明mTORC1和mTORC2在肝脏肿瘤发生和进展中起关键作用。
- 第一代mTOR抑制剂已在肝脏肿瘤治疗中评估疗效,结果不理想。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary liver cancers, including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), are highly lethal tumors, with high worldwide frequency and few effective treatment options. The mammalian target of rapamycin (mTOR) complex is a central regulator of cell growth and metabolism that integrates inputs from amino acids, nutrients, and extracellular signals. The mTOR protein is incorporated into two distinct complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). Specifically, mTORC1 regulates protein synthesis, glucose and lipid metabolism, and autophagy, whereas mTORC2 promotes liver tumorigenesis through modulating the adenine/cytosine/guanine family of serine/threonine kinases, especially the protein kinase B proteins. In human HCC and iCCA samples, genomics analyses have revealed the frequent deregulation of the mTOR complexes. Both in vitro and in vivo studies have demonstrated the key role of mTORC1 and mTORC2 in liver-tumor development and progression. The first-generation mTOR inhibitors have been evaluated for effectiveness in liver-tumor treatment and have provided unsatisfactory results. Current research efforts are devoted to generating more efficacious mTOR inhibitors and identifying biomarkers for patient selection as well as for combination therapies. Here, we provide a comprehensive review of the mechanisms leading to a deregulated mTOR signaling cascade in liver cancers, the mechanisms whereby the mTOR pathway contributes to HCC and iCCA molecular pathogenesis, the therapeutic strategies, and the challenges to effectively inhibit mTOR in liver-cancer treatment. Conclusion: Deregulated mTOR signaling significantly contributes to HCC and iCCA molecular pathogenesis. mTOR inhibitors, presumably administered in association with other drugs, might be effective against subsets of human liver tumors.
引用
- Lu X, Paliogiannis P, Calvisi DF, et al. Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies. Hepatology. 2020. PMID: 32394479. doi:10.1002/hep.31310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。